Cardiovascular risk in clinical decision making Fernando Rodríguez-ArtalejoJosé R. Banegas Invited Commentary 04 October 2007 Pages: 339 - 341
Worksite treatment for cardiovascular disease prevention Michael H. Alderman Invited Commentary 04 October 2007 Pages: 342 - 343
The final nail for sodium reduction Norman M. Kaplan Clinical Trials Report 04 October 2007 Pages: 349 - 350
Aliskiren and blood pressure control in patients with hypertension Donald G. Vidt Clinical Trials Report 04 October 2007 Pages: 351 - 352
Resistant hypertension and aldosteronism Eduardo PimentaDavid A. Calhoun OriginalPaper 04 October 2007 Pages: 353 - 359
Pay for performance: Is it the best way to improve control of hypertension? Tim DoranCatherine Fullwood OriginalPaper 04 October 2007 Pages: 360 - 367
Weight reduction for treatment of obesity-associated hypertension: Nuances and challenges Allyn L. Mark OriginalPaper 04 October 2007 Pages: 368 - 372
Renal protection: Are all antihypertensive drugs comparable? Rashida BlakeLeopoldo RaijIvonne Hernandez Schulman OriginalPaper 04 October 2007 Pages: 373 - 379
JNC-7 guidelines: Are they still relevant? William C. Cushman OriginalPaper 04 October 2007 Pages: 380 - 386
Direct renin inhibitors: Where will they fit in for antihypertensive treatment? Matthew R. Weir Clinical Trials Report 04 October 2007 Pages: 389 - 391
Lifestyle changes and unanswered questions about hypertension and cardiovascular risk George L. Bakris Clinical Trials Report 04 October 2007 Pages: 392 - 392
Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? Radica AlicicKatherine R. Tuttle OriginalPaper 04 October 2007 Pages: 393 - 402
Dual effects of RAS blockade on blood pressure and podocyte function Jochen ReiserPeter Mundel OriginalPaper 04 October 2007 Pages: 403 - 408
Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury? Eberhard RitzLars Christian Rump OriginalPaper 04 October 2007 Pages: 409 - 414
Renin inhibitors: Optimal strategy for renal protection Roland E. Schmieder OriginalPaper 04 October 2007 Pages: 415 - 421
Is RAS blockade routinely indicated in hypertensive kidney transplant patients? Daniel J. Salzberg OriginalPaper 04 October 2007 Pages: 422 - 429
Intensified inhibition of renin-angiotensin system: A way to improve renal protection? Paolo CravediPiero RuggenentiGiuseppe Remuzzi OriginalPaper 04 October 2007 Pages: 430 - 436
